Intercellular adhesion molecule 1 gene K469E polymorphism is associated with coronary heart disease risk: a

Ya-Nan Ji1, Qin Wang, Ping Zhan

  • 1Jiangsu Province Hospital of Traditional Chinese Medicine, 155 Hanzhong Road, Nanjing, 210029, China.

Molecular Biology Reports
|December 29, 2011
PubMed

Insights

The ICAM1 gene K469E polymorphism is linked to increased coronary heart disease (CHD) risk. Specifically, the K allele is a significant risk factor for CHD in Asian and Caucasian populations.

Area of Science:

  • Genetics and Cardiovascular Disease Research
  • Molecular Biology and Epidemiology

Background:

  • Coronary atherosclerosis is a primary cause of coronary heart disease (CHD).
  • Atherosclerotic lesions result from complex polygenic interactions influenced by environmental factors.
  • Previous studies on the association between the ICAM1 gene E469K polymorphism and CHD have yielded conflicting results.

Purpose of the Study:

  • To conduct a systematic review and meta-analysis to clarify the association between the ICAM1 gene E469K polymorphism and coronary heart disease (CHD).

Main Methods:

  • A comprehensive search of PubMed, Embase, and CNKI databases was performed for relevant case-control studies published up to August 2011.
  • Data from twelve eligible studies, including 2,157 cases and 1,952 controls, were extracted and analyzed.
  • Pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated to assess the association.

Main Results:

  • The meta-analysis revealed a significant association between the ICAM1 gene E469K polymorphism and an increased risk of CHD.
  • The K allele demonstrated a higher risk (OR = 1.496, 95% CI = 1.363-1.642) compared to the E allele.
  • Carriers of the K allele showed a significantly increased risk (OR = 1.919, 95% CI = 1.635-2.253) compared to individuals with the EE genotype.

Conclusions:

  • The ICAM1 gene K469E polymorphism is significantly associated with the risk of coronary heart disease (CHD).
  • The K allele of the ICAM1 gene represents a notable risk factor for developing CHD, particularly in Asian and Caucasian populations.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...